ES2173978T3 - Utilizacion de un alcohol graso insaturado. - Google Patents

Utilizacion de un alcohol graso insaturado.

Info

Publication number
ES2173978T3
ES2173978T3 ES95936554T ES95936554T ES2173978T3 ES 2173978 T3 ES2173978 T3 ES 2173978T3 ES 95936554 T ES95936554 T ES 95936554T ES 95936554 T ES95936554 T ES 95936554T ES 2173978 T3 ES2173978 T3 ES 2173978T3
Authority
ES
Spain
Prior art keywords
provides
unsaturated fat
fat alcohol
pharmaceutical composition
alcohol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95936554T
Other languages
English (en)
Inventor
Martin Jackman
Xue-Ping Popp
Friedrich Richter
Fritz Schmook
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27267447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2173978(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB9421612A external-priority patent/GB9421612D0/en
Priority claimed from GB9422306A external-priority patent/GB9422306D0/en
Priority claimed from GBGB9503553.1A external-priority patent/GB9503553D0/en
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2173978T3 publication Critical patent/ES2173978T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

ESTA INVENCION PROPORCIONA UNA COMPOSICION TOPICA, EN FORMA DE EMULSION, QUE INCLUYE UN COMPUESTO DE LA CLASE FK506; UN ALCADIOL ACEPTABLE FISIOLOGICAMENTE, DIOL DE ETER O ALCOHOL DE DIETER QUE CONTIENE HASTA 8 ATOMOS DE CARBONO COMO SOLVENTE PARA EL COMPUESTO DE LA CLASE FK506, UN ALCOHOL GRASO INSATURADO Y AGUA. EN OTRO ASPECTO, ESTA INVENCION PROPORCIONA UNA COMPOSICION FARMACEUTICA TOPICA QUE INCLUYE UN MACROLIDO EN SUSPENSION. EN UN ASPECTO AÑADIDO, ESTA INVENCION PROPORCIONA EL USO DE UN ALCOHOL GRASO INSATURADO PARA ESTABILIZAR UN MACROLIDO EN UNA COMPOSICION FARMACEUTICA.
ES95936554T 1994-10-26 1995-10-26 Utilizacion de un alcohol graso insaturado. Expired - Lifetime ES2173978T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9421612A GB9421612D0 (en) 1994-10-26 1994-10-26 Organic compounds
GB9422306A GB9422306D0 (en) 1994-11-04 1994-11-04 Organic compounds
GBGB9503553.1A GB9503553D0 (en) 1995-02-22 1995-02-22 Organic compounds

Publications (1)

Publication Number Publication Date
ES2173978T3 true ES2173978T3 (es) 2002-11-01

Family

ID=27267447

Family Applications (2)

Application Number Title Priority Date Filing Date
ES01117396T Expired - Lifetime ES2243369T3 (es) 1994-10-26 1995-10-26 Composiciones farmaceuticas.
ES95936554T Expired - Lifetime ES2173978T3 (es) 1994-10-26 1995-10-26 Utilizacion de un alcohol graso insaturado.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES01117396T Expired - Lifetime ES2243369T3 (es) 1994-10-26 1995-10-26 Composiciones farmaceuticas.

Country Status (25)

Country Link
US (1) US6352998B2 (es)
EP (2) EP0786986B1 (es)
JP (3) JP4155593B2 (es)
KR (1) KR100434682B1 (es)
CN (2) CN100335063C (es)
AT (2) ATE214593T1 (es)
AU (1) AU714254B2 (es)
BR (1) BR9509530A (es)
CA (1) CA2200966C (es)
CY (1) CY2211B1 (es)
CZ (1) CZ289773B6 (es)
DE (3) DE19581804T1 (es)
DK (2) DK0786986T3 (es)
ES (2) ES2243369T3 (es)
FI (2) FI119754B (es)
GB (1) GB2308546B (es)
HU (1) HU223840B1 (es)
MX (1) MX9702699A (es)
NO (2) NO316963B1 (es)
NZ (2) NZ331824A (es)
PL (1) PL184750B1 (es)
PT (2) PT786986E (es)
SI (1) SI0786986T1 (es)
SK (1) SK284591B6 (es)
WO (1) WO1996013249A1 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR004480A1 (es) * 1995-04-06 1998-12-16 Amico Derin C D Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
GB9601120D0 (en) 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
CZ267796A3 (cs) 1996-09-12 1998-04-15 Galena A.S. Léčivé přípravky, zejména pro vnitřní aplikaci, ve formě samomikroemulgujících terapeutických systémů
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
TW450810B (en) * 1997-02-20 2001-08-21 Fujisawa Pharmaceutical Co Macrolides antibiotic pharmaceutical composition for preventing and treating skin diseases
DE19744621A1 (de) * 1997-10-09 1999-04-15 Muehlbauer Ernst Kg Mischung zur Verwendung als Wundverband
GB9723669D0 (en) * 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
DE19802205A1 (de) * 1998-01-22 1999-07-29 Beiersdorf Ag Kosmetische und dermatologische Zubereitungen, enthaltend erhöhte Elektrolytkonzentrationen
ID25908A (id) * 1998-03-06 2000-11-09 Novartis Ag Prakonsentrat-prakonsentrat emulsi yang mengandung siklosporin atau makrolida
CA2326222C (en) * 1998-04-27 2008-09-23 Fujisawa Pharmaceutical Co., Ltd. Medicinal compositions
GB9814640D0 (en) * 1998-07-06 1998-09-02 Fujisawa Pharmaceutical Co New use
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
US20070032853A1 (en) * 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
GB0003932D0 (en) * 2000-02-18 2000-04-12 Novartis Ag Pharmaceutical compositions
NZ540000A (en) * 2001-02-16 2007-05-31 Abbott Lab Vascular Entpr Ltd Implants with tacrolimus
GB0108498D0 (en) * 2001-04-04 2001-05-23 Novartis Ag Organic Compounds
AR035293A1 (es) * 2001-08-23 2004-05-05 Novartis Ag Composicion oftalmica.
AR038628A1 (es) * 2002-03-04 2005-01-19 Novartis Ag Composicion oftalmica
GB0218996D0 (en) * 2002-08-14 2002-09-25 Novartis Ag Organic compounds
AU2004212264B9 (en) * 2003-02-17 2009-11-26 Cipla Limited Pharmaceutical patch
US20040214753A1 (en) * 2003-03-20 2004-10-28 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
GB0307867D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
GB0307869D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
GB0307866D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
CN1829510A (zh) * 2003-07-31 2006-09-06 法马西亚和厄普乔恩公司 抗炎剂的可分散性制剂
GB0408070D0 (en) * 2004-04-08 2004-05-12 Novartis Ag Pharmaceutical formulations
BRPI0509708B8 (pt) * 2004-04-08 2021-05-25 Meda Pharma S A R L espuma farmacêutica, composição de espuma de pimecrolimus contendo glicol de hexileno, opcionalmente álcool de oleil, dimetilisosorbídeo e/ou triglicerídeos de cadeia média e uso
GB0508827D0 (en) * 2005-04-29 2005-06-08 Novartis Ag Cosmeceutical composition
WO2008063563A2 (en) 2006-11-16 2008-05-29 Transderm, Inc. Methods of treating keratin hyperproliferation disorders using mtor inhibitors
EP2016935A1 (en) * 2007-07-09 2009-01-21 Intendis GmbH Pharmaceutical composition for topical application of poorly soluble compounds
CN101288643B (zh) * 2008-06-17 2012-11-14 杨喜鸿 含有他克莫司的凝胶剂组合物及其制备方法和药物应用
EP2308468A1 (en) * 2009-10-08 2011-04-13 Novaliq GmbH Novel pharmaceutical composition comprising a macrolide immunosuppressant drug
GB0917816D0 (en) 2009-10-12 2009-11-25 Biotica Tech Ltd Novel compounds and methods for their production
GB0917817D0 (en) 2009-10-12 2009-11-25 Biotica Tech Ltd Novel compounds and methods for their production
EP2366378A1 (en) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulations
WO2012011192A1 (ja) * 2010-07-23 2012-01-26 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
JP5674786B2 (ja) * 2010-07-23 2015-02-25 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
CN102552253A (zh) * 2012-01-17 2012-07-11 唯美度科技（北京）有限公司 一种祛痘用皮肤外用剂
JP6084579B2 (ja) * 2012-01-25 2017-02-22 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
DK2948134T3 (da) * 2013-01-24 2020-06-02 Palvella Therapeutics Inc Sammensætninger til transdermal indgivelse af mtor-inhibitorer
MX367121B (es) * 2013-08-02 2019-08-06 Laboratorio Raam De Sahuayo S A De C V Composición sólida estable de inmunosupresores.
DE102013222164A1 (de) * 2013-10-31 2015-04-30 Deb Ip Limited Stabilisierte multiple Emulsionen als Hautschutzprodukt
US10765665B2 (en) * 2015-11-24 2020-09-08 Melin Jeffrey Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases
CN105663027B (zh) * 2016-04-01 2018-12-18 中国人民解放军广州军区武汉总医院 西罗莫司外用制剂、其制备方法及用途
KR102386585B1 (ko) 2016-04-04 2022-04-13 엠씨2 테라퓨틱스 리미티드 타크롤리무스를 포함하는 국소 조성물
CN110520097B (zh) 2017-01-06 2023-10-27 帕尔维拉治疗股份有限公司 Mtor抑制剂的无水组合物及其使用方法
KR101973065B1 (ko) 2017-09-13 2019-04-26 (주)썬테크 풍력 발전기 및 풍력 발전기의 블레이드 팁
EP3542788A1 (en) 2018-03-19 2019-09-25 MC2 Therapeutics Limited Topical composition comprising calcipotriol and betamethasone dipropionate
KR101995905B1 (ko) 2018-03-27 2019-07-04 (주)썬테크 풍력 발전기 및 풍력 발전기의 발전모터
WO2019233722A1 (en) * 2018-06-08 2019-12-12 Almirall, S.A. Pharmaceutical composition comprising tacrolimus
JP2021530463A (ja) 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物および使用方法
WO2024213629A1 (en) * 2023-04-11 2024-10-17 Bausch Health Ireland Limited Topical compositions

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4299826A (en) 1979-10-12 1981-11-10 The Procter & Gamble Company Anti-acne composition
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
CH677448A5 (es) 1987-11-09 1991-05-31 Sandoz Ag
EP0323042A1 (en) 1987-12-09 1989-07-05 FISONS plc Process to macrocyclic compounds
KR0159766B1 (ko) * 1989-10-16 1998-12-01 후지사와 토모키치로 양모제 조성물
NZ235991A (en) * 1989-11-09 1993-05-26 Sandoz Ltd Macrolide compounds and pharmaceutical compositions thereof
US5061700A (en) 1989-11-16 1991-10-29 Gordon Jay Dow Glyceryl acetate ointment vehicles
WO1991013899A1 (en) 1990-03-12 1991-09-19 Fujisawa Pharmaceutical Co., Ltd. Tricyclo compounds
JPH05507915A (ja) 1990-06-11 1993-11-11 藤沢薬品工業株式会社 特発性血小板減少性紫斑病およびバセドウ病治療薬製造のためのｆｋ５０６等のマクロライド化合物の用途
MY110418A (en) 1990-07-02 1998-05-30 Novartis Ag Heteroatoms-containing tricyclic compounds.
ES2099112T3 (es) 1990-09-04 1997-05-16 Fujisawa Pharmaceutical Co Pomadas que contienen un compuesto triciclico.
US5143918A (en) * 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
PH31204A (en) * 1990-11-02 1998-05-05 Fujisawa Pharmaceutical Co Pharmaceutical composition.
IE65341B1 (en) * 1990-11-08 1995-10-18 Fujisawa Pharmaceutical Co Suspensions containing tricyclic compounds
US5208241A (en) 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
US5247076A (en) 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
US5252732A (en) 1991-09-09 1993-10-12 Merck & Co., Inc. D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity
HUT66531A (en) 1992-05-07 1994-12-28 Sandoz Ag Heteroatoms-containing tricyclic compounds, pharmaceutical prepns contg. them and process for producing them
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
JPH06183970A (ja) * 1992-12-16 1994-07-05 Fujisawa Pharmaceut Co Ltd 医薬用組成物
MY110603A (en) 1993-05-27 1998-08-29 Novartis Ag Tetrahydropyran derivatives
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
WO1995011039A1 (de) 1993-10-22 1995-04-27 Hexal Pharma Gmbh Pharmazeutische zusammensetzung mit cyclosporin a und alpha-tocopherol

Also Published As

Publication number Publication date
EP0786986B1 (en) 2002-03-20
HK1053611A1 (en) 2003-10-31
PL184750B1 (pl) 2002-12-31
US20010031769A1 (en) 2001-10-18
HUT77140A (hu) 1998-03-02
FI971018A0 (fi) 1997-03-11
JP4155593B2 (ja) 2008-09-24
PT1147766E (pt) 2005-11-30
JPH10508588A (ja) 1998-08-25
CZ289773B6 (cs) 2002-04-17
DE69534306T2 (de) 2006-04-27
GB9707484D0 (en) 1997-05-28
NZ331824A (en) 2000-01-28
HU223840B1 (hu) 2005-02-28
DE69534306D1 (de) 2005-08-11
FI119754B (fi) 2009-03-13
DE69525957D1 (de) 2002-04-25
EP1147766A2 (en) 2001-10-24
FI971018L (fi) 1997-04-18
FI119755B (fi) 2009-03-13
KR970706796A (ko) 1997-12-01
PT786986E (pt) 2002-07-31
MX9702699A (es) 1997-06-28
CN1401325A (zh) 2003-03-12
BR9509530A (pt) 1997-10-14
SI0786986T1 (en) 2002-06-30
ES2243369T3 (es) 2005-12-01
PL319599A1 (en) 1997-08-18
NO2004005I2 (no) 2007-06-11
ATE214593T1 (de) 2002-04-15
CN1089233C (zh) 2002-08-21
DE19581804T1 (de) 1998-01-22
SK52097A3 (en) 1997-09-10
US6352998B2 (en) 2002-03-05
CZ123297A3 (en) 1997-08-13
CA2200966A1 (en) 1996-05-09
CY2211B1 (en) 2002-11-08
SK284591B6 (sk) 2005-07-01
NO971951L (no) 1997-04-25
WO1996013249A1 (en) 1996-05-09
DK1147766T3 (da) 2005-08-29
NO316963B1 (no) 2004-07-12
GB2308546A (en) 1997-07-02
EP1147766B1 (en) 2005-07-06
CN1162259A (zh) 1997-10-15
JP5599422B2 (ja) 2014-10-01
DE69525957T2 (de) 2002-11-14
AU3845195A (en) 1996-05-23
NZ295170A (en) 1999-02-25
EP1147766A3 (en) 2001-10-31
CA2200966C (en) 2006-12-19
AU714254B2 (en) 1999-12-23
KR100434682B1 (ko) 2004-08-18
ATE299017T1 (de) 2005-07-15
EP0786986A1 (en) 1997-08-06
NO971951D0 (no) 1997-04-25
CN100335063C (zh) 2007-09-05
GB2308546B (en) 1999-06-02
DK0786986T3 (da) 2002-04-29
NO2004005I1 (no) 2004-09-20
JP2007145860A (ja) 2007-06-14
JP2012131827A (ja) 2012-07-12
FI20071025L (fi) 2007-12-28

Similar Documents

Publication Publication Date Title
ES2173978T3 (es) Utilizacion de un alcohol graso insaturado.
MX9202407A (es) Composicion farmaceutica que contiene un compuesto de alilamina como el agente activo y proceso para su preparacion.
ES2119325T3 (es) Compuestos polienicos, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
ECSP941104A (es) Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
AR033808A1 (es) Una composicion topica de anestesia local y los parches y los envases que la contienen
MX9704550A (es) Formulaciones de medicamentos en aerosol.
PT971705E (pt) Formulacoes de farmacos de terapeutica de substituicao hormonal para aplicacao topica na pele
MX9505182A (es) Composicion terapeutica para aplicacion topica, que contiene un antagonista de la substancia p.
BRPI0509708A (pt) composição de espuma de pimecrolimus contendo glicol de hexileno, opcionalmente álcool de oleil, dimetilisosorbìdeo e/ou triglicerìdeos de cadeia média
CO5160321A1 (es) Novedosas composiciones de tipranavir y ritonavir
AR041826A1 (es) Formulaciones de liberacion prolongada en formas de suspension
ES2104133T3 (es) Composiciones cosmeticas o farmaceuticas que contienen glicerofosfolipidos desacilados para uso topico.
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica
CR5926A (es) Combinaciones de estatina-eter carboxialquilico
ES2045768T3 (es) Composiciones topicas que contienen defibrotida.
CO4940430A1 (es) Compuestos policiclicos que contienen estaurosporina hidrogenada con propiedades farmacologicas convenientes y un efecto inhibidor sobre el crecimiento de las celulas tumorales
ES2130598T3 (es) Preparaciones cosmeticas y/o farmaceuticas.
SV1998000040A (es) Composiciones farmaceuticas ref. pu3210/sv
ES2120667T3 (es) Sal de l-carnitina y composiciones cosmeticas y farmaceuticas que la contienen para tratamiento de dermatosis.
MX9307203A (es) COMPUESTOS ESTEROIDALES DE ACIL-3-CARBOXI-3,5-DIENO-17Ó Y 17ß -SUBSTITUIDOS.
BR0009194A (pt) Composição do resorcinol
ES2038663T3 (es) Un metodo para preparar una composicion para la aplicacion por via topica, destinada al tratamiento de la enfermedad epitelial hiperproliferativa.
ES2156181T3 (es) Utilizacion de un disacarido como estabilizante de mezclas liquidas de proteinas y mezclas liquidas de proteinas que contienen un disacarido.
ES2175099T3 (es) Uso de forskolina o extractos que la contienen en la fabricacion de un medicamento para el tratamiento de la adiccion al alcohol.
AR013115A1 (es) COMPUESTOS DE 2,6-DI-t-BUTIL-4-[(DIMETIL-METOXIFENILSILIL)METIL-OXI]FENOL UTILES EN LA INHIBICION DE LA ARTERIOESCLEROSIS, COMPOSICIONES FARMACEUTICASY USOS EN LA FABRICACION DE MEDICAMENTOS QUE INCLUYEN DICHOS COMPUESTOS

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 786986

Country of ref document: ES